Indications for Weekly Methotrexate Injection (Subcutaneous or Intramuscular)
Methotrexate injection administered once weekly is FDA-approved for rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriasis, and multiple oncologic indications including osteosarcoma, breast cancer, head and neck squamous cell carcinoma, and gestational trophoblastic neoplasia. 1
FDA-Approved Indications
Rheumatologic Conditions
Rheumatoid Arthritis (RA): The FDA-approved starting dosage is 7.5 mg once weekly administered intramuscularly, with escalation to achieve optimal response. 1 Dosages exceeding 20 mg once weekly increase the risk of serious adverse reactions, including myelosuppression. 1
Polyarticular Juvenile Idiopathic Arthritis (pJIA): The recommended starting dosage is 10 mg/m² once weekly administered subcutaneously or intramuscularly, with escalation to achieve optimal response. 1 Dosages over 30 mg/m² per week may result in increased risk of serious adverse reactions, including myelosuppression. 1
Dermatologic Conditions
- Psoriasis: The FDA-approved dosage range is 10 mg to 25 mg intramuscularly or intravenously once weekly until adequate response is achieved. 1 Once optimal clinical response has been achieved, the dosage should be reduced to the lowest possible regimen. 1
Oncologic Indications
Osteosarcoma: Typically 12 g/m² (maximum 20 g/dose) as an intravenous infusion over 4 hours as part of combination chemotherapy, with leucovorin rescue required. 1
Breast Cancer: 40 mg/m² intravenously as a component of a cyclophosphamide- and fluorouracil-based multi-drug regimen. 1
Squamous Cell Carcinoma of Head and Neck: 40 to 60 mg/m² intravenously once weekly. 1
Gestational Trophoblastic Neoplasia: For low-risk GTN, 30 mg/m² to 200 mg/m² or 0.4 mg/kg to 1 mg/kg intravenously or intramuscularly; for high-risk GTN, 300 mg/m² over 12 hours as an intravenous infusion as part of multi-drug regimen. 1
Off-Label but Guideline-Supported Indications
Disseminated Sarcoidosis
Methotrexate 10–15 mg once weekly is endorsed by multinational rheumatology guidelines as a steroid-sparing agent for disseminated sarcoidosis. 2
The 2021 European Respiratory Society (ERS) clinical practice guidelines list methotrexate as a standard immunosuppressive option with a typical starting dose of 10–15 mg once weekly. 2
Dose escalation by 5 mg every 2–4 weeks to a therapeutic range of 20–30 mg/week is recommended based on clinical response and tolerability. 2
Route Selection: When to Use Parenteral Administration
The decision to use subcutaneous or intramuscular methotrexate rather than oral administration should be based on specific clinical scenarios:
Primary Indications for Parenteral Route
Inadequate clinical response to oral methotrexate at therapeutic doses (typically after failure at 15–20 mg/week orally). 3, 2
Gastrointestinal intolerance to oral methotrexate, including nausea, vomiting, or other GI adverse effects. 2, 4, 5
Poor adherence to oral therapy. 2
Doses exceeding 20 mg/week, where oral bioavailability becomes unreliable. 2
Evidence Supporting Parenteral Administration
Starting with 15 mg/week subcutaneous versus oral methotrexate in early RA was associated with higher clinical efficacy but more withdrawal due to toxicity. 3
The 2021 American College of Rheumatology guidelines conditionally recommend transitioning to subcutaneous methotrexate rather than adding or switching to another DMARD when oral therapy fails to achieve target response. 2
Parenteral administration provides higher bioavailability and may reduce gastrointestinal toxicity. 2, 4, 5
A retrospective survey found significant reductions in frequency and intensity of nausea and frequency of discomfort when switching from oral to subcutaneous methotrexate. 5
Critical Safety Considerations
Mandatory Co-Administration
Folic acid or folinic acid supplementation must be administered to reduce the risk of methotrexate adverse reactions across all indications. 1
At least 5 mg folic acid per week is strongly recommended, preferably as daily folic acid on days other than the methotrexate dose day. 2
Dosing Frequency Warning
Methotrexate must be administered weekly, not daily—dosing errors are a major cause of life-threatening toxicity. 2
This is an absolute critical safety point that must be emphasized to all patients and caregivers. 2